BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors by Pennisi M.S. et al.
ORIGINAL RESEARCH
published: 13 August 2019
doi: 10.3389/fonc.2019.00764
Frontiers in Oncology | www.frontiersin.org 1 August 2019 | Volume 9 | Article 764
Edited by:
Massimo Breccia,
Sapienza University of Rome, Italy
Reviewed by:
Valentin Garcia-Gutierrez,
Ramón y Cajal University
Hospital, Spain
Rehan Khan,
Mayo Clinic Arizona, United States
Alejandro Majlis,
Las Condes Clinic, Chile
*Correspondence:
Paolo Vigneri
vigneripaolo@gmail.com
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Hematologic Malignancies,
a section of the journal
Frontiers in Oncology
Received: 03 April 2019
Accepted: 29 July 2019
Published: 13 August 2019
Citation:
Pennisi MS, Stella S, Vitale SR,
Puma A, Di Gregorio S, Romano C,
Tirrò E, Massimino M, Antolino A,
Siragusa S, Mannina D, Impera S,
Musolino C, Mineo G, Martino B,
Zammit V, Di Raimondo F, Manzella L,
Stagno F and Vigneri P (2019)
BCR-ABL1 Doubling-Times and
Halving-Times May Predict CML
Response to Tyrosine Kinase
Inhibitors. Front. Oncol. 9:764.
doi: 10.3389/fonc.2019.00764
BCR-ABL1 Doubling-Times and
Halving-Times May Predict CML
Response to Tyrosine Kinase
Inhibitors
Maria Stella Pennisi 1,2†, Stefania Stella 1,2†, Silvia Rita Vitale 1,2†, Adriana Puma 1,2,
Sandra Di Gregorio 1,2, Chiara Romano 1,2, Elena Tirrò 1,2, Michele Massimino 1,2,
Agostino Antolino 3, Sergio Siragusa 4, Donato Mannina 5, Stefana Impera 6,
Caterina Musolino 7, Giuseppe Mineo 8, Bruno Martino 9, Valentina Zammit 10,
Francesco Di Raimondo 10,11, Livia Manzella 1,2, Fabio Stagno 10 and Paolo Vigneri 1,2*
1Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 2Center of Experimental Oncology
and Hematology, Azienda Ospedaliera Universitaria (A.O.U.) Policlinico - Vittorio Emanuele, Catania, Italy, 3Department of
Transfusional Medicine, Maria Paternò-Arezzo Hospital, Ragusa, Italy, 4Division of Hematology, Azienda Ospedaliera
Universitaria (A.O.U.) Policlinico “P. Giaccone”, University of Palermo, Palermo, Italy, 5Division of Hematology, Papardo
Hospital, Messina, Italy, 6Division of Oncology and Hematology, ARNAS Garibaldi-Nesima, Catania, Italy, 7Division of
Hematology, Azienda Ospedaliera Universitaria (A.O.U.) Policlinico “G. Martino”, University of Messina, Messina, Italy,
8Division of Hematology, San Vincenzo Hospital, Taormina, Italy, 9Division of Hematology, Grande Ospedale Metropolitano,
Reggio Calabria, Italy, 10Division of Hematology and Bone Marrow Transplant, Azienda Ospedaliera Universitaria (A.O.U.)
Policlinico - Vittorio Emanuele, Catania, Italy, 11Department of Surgery, Medical and Surgical Specialties, University of
Catania, Catania, Italy
In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular
monitoring to evaluate disease response and provide timely interventions for patients
failing to achieve the desired outcomes. We wanted to determine whether measuring
BCR-ABL1 mRNA doubling-times (DTs) could distinguish inconsequential rises in the
oncogene’s expression from resistance to tyrosine kinase inhibitors (TKIs). Thus, we
retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients
receiving imatinib mesylate (IM) as a first line treatment. Patients were subdivided in two
groups: those with a confirmed rise in BCR-ABL1 transcripts without MR3.0 loss and
those failing IM. We found that the DTs of the former patients were significantly longer
than those of patients developing IM resistance (57.80 vs. 41.45 days, p = 0.0114).
Interestingly, the DT values of individuals failing second-generation (2G) TKIs after
developing IM resistance were considerably shorter than those observed at the time of
IM failure (27.20 vs. 41.45 days; p= 0.0035). We next wanted to establish if decreases in
BCR-ABL1 transcripts would identify subjects likely to obtain deep molecular responses.
We therefore analyzed the BCR-ABL1 halving-times (HTs) of a different cohort comprising
174 individuals receiving IM in first line and observed that, regardless of the time
point selected for our analyses (6, 12, or 18 months), HTs were significantly shorter
in subjects achieving superior molecular responses (p = 0.002 at 6 months; p <
0.001 at 12 months; p = 0.0099 at 18 months). Moreover, 50 patients receiving
2G TKIs as first line therapy and obtaining an MR3.0 (after 6 months; p = 0.003)
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or an MR4.0 (after 12 months; p = 0.019) displayed significantly shorter HTs than
individuals lacking these molecular responses. Our findings suggest that BCR-ABL1 DTs
and HTs are reliable tools to, respectively, identify subjects in MR3.0 that are failing their
assigned TKI or to recognize patients likely to achieve deep molecular responses that
should be considered for treatment discontinuation.
Keywords: Chronic Myeloid Leukemia, doubling-time, halving-time, tyrosine kinase inhibitors, BCR-ABL1/ABL1IS
INTRODUCTION
Unlike other solid or hematologic malignancies, Chronic
Myeloid Leukemia (CML) is characterized by a single pathogenic
alteration: the BCR-ABL1 chimeric oncogene (1–6). BCR-ABL1
is generated by a translocation involving the breakpoint cluster
region (BCR) and the Abelson (ABL1) genes localized on
chromosomes 22 and 9, respectively. The ensuing Philadelphia
chromosome (Ph+) encodes for a constitutively active tyrosine
kinase that promotes cell proliferation, modifies the actin
cytoskeleton and modulates the interaction between leukemic
cells and the bone marrow microenvironment (7–12).
While first- and second-generation (2G) tyrosine kinase
inhibitors (TKIs) have generated unprecedented results for
individuals diagnosed with chronic phase CML, solid evidence
indicates that patients who do not achieve early molecular
responses often display inferior outcomes, with increased
risk of disease relapse, progression and death (13, 14).
Hence, they require alternative forms of treatment (15).
Branford et al. have previously shown that short BCR-ABL1
doubling-times (DTs) (expressed in number of days) may be
associated with CML progression to blast crisis (BC) (16).
On the other hand, individuals who achieve a deep molecular
response (MR4.0 or better) might be candidates for treatment
discontinuation (17, 18).
Based on these data, we analyzed the DT of the BCR-ABL1
transcripts in 305 chronic phase CML patients receiving Imatinib
Mesllate (IM) as first line treatment to establish if different rises
in BCR-ABL1 transcripts could distinguish clinically negligible
increases in oncogene levels from those indicative of TKI
resistance. The 305 subjects were subdivided in two groups:
those with a confirmed elevation in BCR-ABL1 transcripts
without major molecular response (MR3.0) loss, and those failing
IM according to the latest European Leukemia Net (ELN)
guidelines (19).
We also wanted to establish if a decrease in BCR-ABL1
expression—defined as BCR-ABL1 halving-time (HT)—could be
employed to discern which CML patients were likely to achieve
deep molecular responses and could be considered for TKI
discontinuation. To this end, we analyzed the HTs of 174 patients
receiving IM in first line, and analyzed their BCR-ABL1 values at
6, 12, and 18 months of treatment.
Finally, as previous randomized phase III trials (20, 21) have
suggested, employing 2G TKIs in place of IM as first line
treatment for chronic phase CML induces faster and deeper
clinical andmolecular responses. Hence, we also analyzed the HT
values of 50 patients receiving 2GTKIs as initial therapy for CML.
METHODS
Patients and Treatment
Five hundred and twenty-nine early chronic phase CML patients
were included in this study. Patients baseline characteristics are
summarized in Supplementary Table 1. Subjects were followed
in 10 Divisions of Hematology comprised in the SCREEN (Sicily
and Calabria CML REgional ENterprise) Network from January
2005 to December 2018. Molecular monitoring was centralized
in the Center of Experimental Oncology and Hematology of the
A.O.U. Policlinico-Vittorio Emanuele. Four hundred seventy-
nine patients received IM (400 mg/daily) whereas 50 were
treated in first line with a 2G TKI. Specifically, 11 received
dasatinib (DAS) 100 mg/daily while 39 received nilotinib (NIL)
300mg twice/daily. Of the 479 individuals receiving IM, 305
were included for the calculation of BCR-ABL1 DTs, while the
remaining 174, the only individuals experiencing a continuous
decrease of their oncogenic transcripts, were recruited to
estimate BCR-ABL1 HTs. Responses to therapy were evaluated
according to the 2013 ELN criteria (19). The research ethics
committee of each recruiting institution reviewed and approved
the study protocol. The study was conducted according to the
Helsinki Declaration.
Molecular Response Definitions
BCR-ABL1 transcripts were measured in peripheral blood
samples, at diagnosis and every 3 months thereafter using Real-
Time quantitative PCR (Q-PCR) as previously described (22–24).
All collected samples were subjected to Q-PCR using the TaqMan
platform and ABL1 as a reference gene. Only individuals with
the common e13a2 and/or e14a2 BCR-ABL1 transcripts were
included in our analysis. BCR-ABL1 values were converted to the
IS as previously described (24, 25). MR3.0 andMR4.0 were defined
by BCR-ABL1/ABL1IS values ≤0.1% and ≤0.01%, respectively,
with no <10,000 ABL1 copies (26).
For the DT and HT analysis, we considered patients with
BCR-ABL1/ABL1IS levels <10% since previous studies have
shown that values ≥10% are quantitatively inaccurate (27). An
increase of the BCR-ABL1/ABL1IS transcript was defined as a
>2-fold (if BCR-ABL1/ABL1IS levels were ≥0.01%) or 5-fold (if
BCR-ABL1/ABL1IS levels were <0.01%) rise in two consecutive
analyses (without therapeutic intervention).
For the HTs analysis, a reduction of BCR-ABL1/ABL1IS
transcripts was defined as a >2-fold (if BCR-ABL1/ABL1IS
levels were ≥0.01%) or 5-fold (if BCR-ABL1/ABL1IS levels were
<0.01%) decrease in two consecutive analyses.
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Doubling-Time and Halving-Time
Calculation and Statistical Analyses
To calculate BCR-ABL1DTs we employed the following formula:
DT = ln2/k, where (k) is the fold BCR-ABL1 rise divided by
the number of days over which the rise occurred [k = (ln(b)
– ln(a))/d], with (a) the value before the rise, (b) the value
at the rise, and (d) days (16). Similarly, the HT formula was
calculated using the following formula: HT= -ln2/k, where (k) is
calculated as reported above (28). Groups were compared using
the unpaired t-test and the Kruskal-Wallis test employing the
GraphPad software (version 5.0a).
RESULTS
BCR-ABL1 Doubling-Times Distinguish
Patients With Negligible BCR-ABL1
Increases From Those Failing IM
To establish if BCR-ABL1 DTs could determine the clinical
significance of a rise in the transcripts of the chimeric oncogene,
we analyzed the evolution of BCR-ABL1 mRNAs in 305 patients
with chronic phase CML that had achieved a major molecular
response (MR3.0) after receiving standard dose IM as first line
treatment. The rates of treatment response of these individuals
are summarized in Table 1.
Of the 305 patients, 187 (61.3%) maintained their previously
achievedMR3.0 despite an increase in BCR-ABL1 levels, while 118
(38.7%) failed IM according to the 2013 ELN recommendations
(Figure 1A). Statistical analyses determined that the BCR-ABL1
DTs were significantly longer for individuals maintaining an
MR3.0 as compared to those observed in subjects failing IM (57.80
vs. 41.45, p= 0.0114) (Figure 1B and Table 2).
Of the 118 individuals that failed IM, 50 received DAS,
47 received NIL, 11 (6 patients with T315I mutation and 5
subjects with compound mutations resistant to DAS and NIL)
received ponatinib and 10 were subjected to an allogeneic stem
cell transplant. Within the 97 individuals treated with a 2G
TKI, 76 (78.3%) achieved an optimal response while 21 (21.7%)
developed resistance to second line treatment (Figure 1A). We
calculated the DTs for this last selected patient cohort and found
a significant difference between the median DTs observed at the
time of first or second treatment failure (41.45 vs. 27.20 days;
p= 0.0035) (Figure 1C and Table 3).
These data suggest that DT analysis may discriminate
clinically negligible increases in BCR-ABL1 levels from
those associated with IM failure. Our data also confirm
that CML patients failing two lines of treatment have an
aggressive and rapidly proliferating disease that requires urgent
medical attention.
BCR-ABL1 Halving-Times Identify Patients
Likely to Achieve Deep Molecular
Responses With IM
Consolidated evidence suggests that CML patients achieving
and maintaining deep molecular responses (≥MR4.0) may be
considered for treatment discontinuation (29). To evaluate
if BCR-ABL1 HTs could be employed to identify individuals
TABLE 1 | Rates of treatment responses.
DT IM first line
(305 pz) (%)
HT IM first line
(174 pz) (%)
HT 2G TKIs first line
(50 pz) (%)
CCyR 47.8 66.3 71.7
MMR 35.4 55.8 58.7
DMR 46.0 57.0 61.0
EFS 58.1 81.9 100
PFS 96.6 98.2 100
OS 91.3 92.4 95.6
CCyR, complete cytogenetic response; MMR, major molecular response; DMR, deep
molecular response; EFS, events free survival; PFS, progression free survival; OS,
overall survival.
likely to obtain molecular responses ≥MR4.0, we analyzed the
reduction in BCR-ABL1 transcripts of 174 subjects receiving
standard dose IM and selected three different time-points: 6, 12,
and 18 months of treatment. The rates of treatment response for
these patients are summarized in Table 1.
As most patients were evaluated at multiple time points, the
overall number of samples analyzed to calculate BCR-ABL1 HTs
was 305. Specifically, samples from 90 individuals were available
after 6 months of IM (50 without MR3.0, 40 in MR3.0), 111
specimens were accessible after 12 months (22 without MR3.0, 89
in MR3.0) and 104 samples could be tested after 18 months (39
without MR4.0 and 65 in MR4.0) (Figure 2A). At the 6-month
time point, the median HT for the 50 patients not in MR3.0
was 39 days (range 14.9–142.6) compared to 21.90 days (range
13.0–131.6) for the 40 individuals with an MR3.0. This difference
was statistically significant (p = 0.002) (Figure 2B and Table 4).
After 12 months of IM, we compared the BCR-ABL1 HTs of
the 22 patients without MR3.0 to those of the 89 individuals
with MR3.0. Median HTs were significantly longer for patients
without MR3.0 97.65 days (range 26.4–354.3) as compared to
individuals in MR3 30.60 days (range 7.8–156.1) (p < 0.0001)
(Figure 2C and Table 4). Similarly, after 18 months of IM, HTs
in the 39 subjects in MR3.0 were 76.70 days (range 15.1–179.9),
a significantly higher value than that recorded in the 65 patients
in MR4.0 (50.10 days; range 15.5–192.2) (p= 0.0099) (Figure 2D
and Table 4).
Hence, calculating BCR-ABL1HTs may prove of clinical value
to rapidly recognize CML patients that are likely to achieve deep
molecular responses on IM.
BCR-ABL1 Halving-Times Identify Patients
Likely to Achieve Deep Molecular
Responses With 2G TKIs
To investigate the differences in the velocity of BCR-ABL1
reduction in patients receiving 2G TKIs, we measured the
HTs of 50 individuals treated in first line with DAS or NIL
(Figure 3A). The rates of treatment response for these subjects
are summarized in Table 1. In detail, patients without MR3.0
after 6 months of treatment had a BCR-ABL1 HT of 43.50 days
(range 21.4–195.1) vs. 22.50 days (range 13.2–116.6) for those
in confirmed MR3.0 after 6 months (p = 0.003) (Figure 3B and
Table 5). We next repeated this assessment on 26 patients that
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FIGURE 1 | BCR-ABL1 DTs in patients failing IM and 2G TKIs in second line. (A) Three hundred five patients with chronic phase CML presenting BCR-ABL1/ABL1IS
values ≤0.1% on IM therapy were included in this analysis. One hundred eighteen patients failed IM and switched to a different therapy, while 187 individuals
displayed an increase in BCR-ABL1 levels but retained their previously acquired MR3.0. Of the 118 individuals failing IM, 21 also failed the 2G TKI prescribed in second
line while 76 responded to treatment. The remaining 21 patients either received ponatinib (n = 10) or were subjected to allogeneic human stem cell transplant (HSCT:
n = 11). Boxplots delimited by the 25th (lower) and 75th (upper) percentile comparing BCR-ABL1 DTs in the IM failure group and in subjects maintaining their MR3.0
(B) or in the IM failure group and in individuals failing 2G TKIs in second line (C). Horizontal lines above and below each boxplot indicate the 5th and 95th percentile,
respectively. Numbers inside each boxplot represent median values observed within each patient cohort. The reported p-values indicate statistical significance
between the two patient groups included in each panel.
had received 2G TKIs for 12 months: 17 were without MR4.0
while 9 had attained an MR4.0. Median BCR-ABL1 HTs were
91.60 days for the former patients (range 20.3–290.9) vs. 42.80
days for the latter group (range 19.8–66.5) (p= 0.019) (Figure 3C
and Table 5).
These results confirmed the clinical usefulness of assessing
BCR-ABL1 molecular kinetics in CML patients receiving
2G TKIs.
DISCUSSION
Disease risk (measured with the Sokal, EURO or EUTOS Long-
Term Survival score), BCR-ABL1/GUSIS transcripts at diagnosis,
individual comorbidities and expected patient compliance are
good parameters to select between IM and 2G TKIs for the initial
treatment of chronic phase CML (19). Moreover, reductions
in BCR-ABL1/ABL1IS transcripts are pivotal determinants of
therapeutic efficacy regardless of the prescribed TKI, as indicated
in the latest ELN guidelines (19). However, it is currently
difficult to identify the correct therapeutic approach for the
heterogeneous group of patients with a TKI response classified
as “warning.”
As previously reported by Branford et al. (16), an increase
in BCR-ABL1 transcripts may be predictive of a potential loss
of IM response. Specifically, in the Australian analysis, short (9
days) BCR-ABL1 DTs were indicative of disease evolution to BC
or of IM discontinuation/interruption, while longer (48 days)
DTs were associated with TKI failure due to point mutations in
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TABLE 2 | Comparison of BCR-ABL1 DTs in patients with transcript increases but different clinical outcomes.
Clinical context of
BCR-ABL1 rise
No of patients DT (range) Median BCR-ABL1/ABL1IS
before rise (range)
Median BCR-ABL1/ABL1IS
after rise (range)
p-value
BCR-ABL1 increase
with IM failure
118 41.45 (8.4–281.9) 0.076 (0.002–0.0943) 0.460 (0.110–48.93) p = 0.0114
BCR-ABL1 increase w/o
MR3.0 loss
187 57.80 (14.3–356.2) 0.006 (0.00–0.031) 0.018 (0.002–0.100)
TABLE 3 | Comparison of BCR-ABL1 DTs in patients failing first and second line treatment with IM and 2G TKIs.
Clinical context of
BCR-ABL1 rise
No of patients DT (range) Median BCR-ABL1/ABL1IS
before rise (range)
Median BCR-ABL1/ABL1IS
after rise (range)
p-value
BCR-ABL1 increase
with IM failure
118 41.45 (8.4–281.9) 0.076 (0.002–0.0943) 0.460 (0.110–48.93) p = 0.0035
Second line failure 21 27.20 (2.5–56.3) 0.149 (0.0002–5.85) 4.850 (0.48–20.12)
FIGURE 2 | Differences in BCR-ABL1 HTs between patients able or unable to achieve MR3.0 or MR4.0 at different time points. (A) Flow chart depicting BCR-ABL1
HTs calculated, at different time points, for a total of 174 CML patients receiving standard dose IM. Boxplots delimited by the 25th (lower) and 75th (upper) percentile
show HTs calculated after 6 (B), 12 (C), and 18 (D) months of IM. Horizontal lines above and below each boxplot indicate the 5th and 95th percentile, respectively.
Numbers inside each boxplot represent median values observed within each patient cohort. The reported p-values indicate statistical significance between the two
patient groups included in each panel.
the BCR-ABL1 kinase domain without progression to BC. To
support these results in a different patient cohort, we calculated
the BCR-ABL1 DTs of 305 CML patients receiving standard
dose IM in first line. As our patient series was devoid of
subjects progressing to BC, we could not confirm the findings
of Branford et al. on the extremely brief DT detected in
patients with disease evolution. However, in agreement with their
results, we found that patients failing IM displayed DTs <42
days, a value extremely similar to that reported by Branford
et al. These findings suggest that individuals with DTs of 42–
48 days should be quickly considered for a change of therapy
(Figure 1). In addition, to establish if IM failure correlated
with alterations in the sequence of the BCR-ABL1 kinase
domain, we analyzed this patient cohort by clonal sequencing.
We found resistant mutations (F317L, Y253H, M351T) in 3
patients and alternatively spliced variants (i.e., 35 bp insertion),
in other 5 individuals (data not shown). Our results are in
line with those previously reported by Yuda et al. showing
that a 35 bp insertion might be correlated with loss of IM
response (30).
In our cohort, patients failing IM were treated with 2G TKIs
(94 in total) or received ponatinib (11 in total). These treatment
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TABLE 4 | Comparison of BCR-ABL1 HTs at different time points in patients treated with IM and stratified according to the achieved molecular responses.
Clinical context at time of
BCR-ABL1 decrease
No of samples
analyzed
HT (range) Median BCR-ABL1/ABL1IS
before the decrease (range)
Median BCR-ABL1/ABL1IS
after the decrease (range)
p-value
IM w/o MR3.0 by 6 months 50 39.00 (14.9–142.6) 1.760 (0.210–9.540) 0.267 (0.115–0.989) p = 0.002
IM with MR3.0 by 6 months 40 21.90 (13.0–131.6) 0.524 (0.109–5.364) 0.033 (0.001–0.098)
IM w/o MR3.0 by 12 months 22 97.65 (26.4–354.3) 1.320 (0.93–9.60) 0.621 (0.188–1.030) p < 0.001
IM with MR3.0 by 12 months 89 30.60 (7.8–156.1) 0.263 (0.112–4.244) 0.040 (0.001–0.098)
IM w/o MR4.0 by 18 months 39 76.70 (15.1–179.9) 0.100 (0.021–1.002) 0.038 (0.011–0.099) p = 0.0099
IM with MR4.0 by 18 months 65 50.10 (15.5–192.2) 0.011 (0.000–0.678) 0.003 (0.000–0.033)
FIGURE 3 | BCR-ABL1 HTs in patients receiving 2G TKIs as first-line therapy. (A) BCR-ABL1 HTs were calculated in a total of 62 samples evaluated after 6 (n = 36) or
12 (n = 26) months of treatment with 2G TKIs. Boxplots delimited by the 25th (lower) and 75th (upper) percentile indicate HTs comparing individuals with or without an
MR3.0 after 6 months (B) or subjects with or without an MR4.0 after 12 months (C) of therapy. Horizontal lines above and below each boxplot indicate the 5th and
95th percentile, respectively. Numbers inside each boxplot represent median values observed within each patient cohort. The reported p-values indicate statistical
significance between the two patient groups included in each panel.
decisions were guided by mutational analyses performed at
the time of drug failure, as the 11 subjects given ponatinib
displayed the T315I substitution (6 patients) or compound
mutations (Y253H/F317L in 2 subjects, V299L/M351T in 3
patients) responsive to the drug, as previously reported by
Zabriskie et al. (31).
Individuals failing both IM and a 2G TKI displayed a
significantly lower BCR-ABL1 DT at the time of second line
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TABLE 5 | Comparison of BCR-ABL1 HTs at different time points in patients treated with 2G TKIs and stratified according to the achieved molecular responses.
Clinical context at time of
BCR-ABL1 decrease
No of samples
analyzed
HT (range) Median BCR-ABL1/ABL1IS
before the decrease (range)
Median BCR-ABL1/ABL1IS
after the decrease (range)
p-value
2G TKIs w/o MR3.0 by 6 months 11 43.50 (21.4–195.1) 1.515 (0.336–6.664) 0.250 (0.120–1.483) p = 0.003
2G TKIs with MR3.0 by 6 months 25 22.50 (13.2–116.6) 0.451 (0.106–4.85) 0.046 (0.002–0.098)
2G TKIs w/o MR4.0 by 12
months
17 91.60 (20.3–290.9) 0.086 (0.018–4.850) 0.031 (0.013–0.095) p = 0.0019
2G TKIs w/o MR4.0 by 12
months
9 42.80 (19.8–66.5) 0.045 (0.011–3.083) 0.005 (0.003–0.010)
failure (27.20 vs. 41.45 days; p= 0.0035) indicative of a biological
evolution toward a more aggressive disease (Figure 1).
Several studies (17, 29, 32–34) have shown that patients
who maintain undetectable minimal residual disease may be
candidates for therapy discontinuation. However, the early
identification of such patients remains a controversial issue.
Hence, as suggested by Branford et al. (28), we analyzed
the reduction in oncogenic transcripts after 6, 12, and 18
months of IM to calculate a BCR-ABL1 HT and establish if
this parameter is useful to recognize patients that should be
considered for treatment cessation. Our data confirm that TKI-
sensitive disease follows a biphasic decline (a rapid reduction
during the first 6 months followed by a more gradual decline
thereafter) as previously reported [(35); Figures 2, 3]. This
pattern is likely attributable to an initial decrease in the number
of differentiated Ph+ neutrophils followed by a reduction in
the rate of leukemic stem cell turnover (28, 36, 37). Thus, the
early (at 6 months) achievement of a major molecular response
followed by a further BCR-ABL1 decrease to a deep molecular
response (≥MR4.0) may be considered a selective parameter
favoring the rapid identification of individuals potentially eligible
for TKI discontinuation.
Both the DASISION and the ENESTnd studies (20, 21) have
suggested that the use of 2G TKIs as first line treatment for
chronic phase CML induces faster and deeper responses than
IM. To compare the BCR-ABL1 decline in patients treated with
IM or 2G TKIs, we measured the oncogene’s HTs in individuals
receiving DAS or NIL as first line treatment. As expected, we
found no differences in the velocity of BCR-ABL1 reduction
between patients achieving the same molecular responses (MR3.0
at 6 months), regardless of the TKI they were receiving (21.90
vs. 22.50 days). However, we detected a sizeable difference in
the number of subjects attaining this response: 44% in the IM
group vs. 69% in the 2G TKI group. This finding confirms that
individuals displaying excellent responses to IM will obtain a
comparable benefit to that achievable with 2G TKIs but that
the overall number of these subjects is clearly inferior to that
attainable with DAS or NIL. These differences are amplified
at later time points, with only 13% of IM-treated individuals
achieving an MR4.0 at 12 months (data not shown) compared
to 35% for those receiving 2G TKIs. Furthermore, from the
12-month time point onwards, BCR-ABL1 HTs were constantly
shorter in patients treated with 2G TKIs explaining the higher
number of deep molecular responses observed with these drugs.
However, our data suggest that, regardless of the type of inhibitor,
after 12months of TKI therapy aHT value of 40 days is associated
with a higher probability of achieving a deep molecular response.
In summary, BCR-ABL1 DTs and HTs are easily
measurable molecular parameters that rely on the timely
computation of the variations in BCR-ABL1 transcripts
that are routinely measured in real life CML monitoring.
Both molecular indexes can be of great value in complex
clinical situations i.e., in interpreting a rise in BCR-ABL1
levels in patients that have achieved an MR3.0 and in
discriminating patients that exhibit modest declines in their
oncogenic transcripts from those who will likely achieve a
deep molecular response and might therefore be eligible for
TKI discontinuation.
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